Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220297 · ClinicalTrials.gov registry record · Phase 2
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01220297: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT01220297 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01220297, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease (GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)
Interventions
- DRUG Sirolimus
- DRUG Etoposide
- DRUG Carmustine
- DRUG Mycophenolate mofetil (MMF)
- DRUG Cyclophosphamide (Cyclo, CY)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220297
The ClinicalTrials.gov registry entry for NCT01220297 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT01220297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220297 about?
NCT01220297 is a clinical study titled "Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT". A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease (GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high risk non-Hodgkin lymph...
What is the current status of trial NCT01220297?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2006-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01220297?
The interventions under investigation include: Sirolimus (DRUG), Etoposide (DRUG), Carmustine (DRUG), Mycophenolate mofetil (MMF) (DRUG), Cyclophosphamide (Cyclo, CY) (DRUG).
Who is sponsoring clinical trial NCT01220297?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.